Press Release (ePRNews.com) - NEW YORK - Oct 28, 2019 - Dr. Steven Fox, who treats supermodels, families of heads of state, and famous corporate leaders, has created a technique for veneers that changes the smile into an age-defying look. Dr. Fox incorporates digital photography, special light, custom shape and color to design a smile unique to each patient’s facial anatomy.
About Dr. Fox:
Widely viewed as an icon in the dental profession and credited for revolutionizing oral care on a global basis, Dr. Fox has collaborated with the U.S. government and the American Dental Association to develop and commercialize many of the products used in oral care today. He is the only doctor in New York City who taught cosmetic dentistry, and served on the faculties of the Harvard School of Dental Medicine The NYU School of Dentistry, as an officer of Harvard University and on a tech board at The University of Pennsylvania. The author of the book “Dentistry in the 21st Century,” and an accomplished business entrepreneur, Dr. Fox has frequently appeared on national and international television programming such as CNBC, Fox News, and CNN; and has been featured in hundreds of newspapers and magazines, including The Wall Street Journal and Forbes Magazine.
As Founder, CEO and Chairman of Enamelon, Inc., he helped to pioneer the first technology to re-mineralize tooth structure with liquid calcium, spearheaded its creation as an over-the-counter product and took the company public on a national stock exchange, raising $70 million over an eight-year period. Recognized for his groundbreaking work in advancing oral care, Dr. Fox is the recipient of the United States Senate Medal of Freedom and the Ernst and Young Entrepreneur of the Year Award, in addition to owning and operating New York City’s premier cosmetic dentistry practice.
For more information, please contact:
Dr. Steven Fox, CEO
About Akelos Inc.
Akelos Inc. is a biopharmaceutical clinical company focused on the translation of innovative science into treatment. The company currently is developing novel non-opioid drugs for the treatment of neuropathic pain. The goal of Akelos is to address some of today’s most pressing areas of unmet needs.